Evidence map›Paper›PMID 40650568›Full record

ReviewJournal of industrial microbiology & biotechnology2024

Towards engineering agaricomycete fungi for terpenoid production.

Riccardo Iacovelli, Dominik Mojzita, Peter Richard, Yvonne Nygård

Abstract readReview
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How to get the most out of fungal biotechnology?Fungal biology and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Riccardo IacovelliVTT Technical Research Centre of Finland, 02150 Espoo, Finland.ORCID 0000-0003-4819-2251
Dominik MojzitaVTT Technical Research Centre of Finland, 02150 Espoo, Finland.ORCID 0000-0001-6078-4503
Peter RichardVTT Technical Research Centre of Finland, 02150 Espoo, Finland.ORCID 0000-0003-0922-6092
Yvonne NygårdVTT Technical Research Centre of Finland, 02150 Espoo, Finland.ORCID 0000-0001-6117-0343

Funding

Novo Nordisk Foundation #0086472
6 · The paper itself

Abstract

Since ancient times, humans have harnessed the vast metabolic abilities of fungi to produce food, beverages, and medicines. Biotechnology and genetic engineering have opened new avenues to tailor and enhance these abilities, transforming fungi into powerful industrial workhorses. In this minireview, we focus on the biotechnological potential of Agaricomycetes, a class of basidiomycete fungi that includes the so-called 'true' mushrooms. Although many species are widely used in the food sector, their broader potential in biotechnology remains largely untapped. These fungi naturally produce a diverse array of metabolites with promising applications across various industries. Here, we highlight their ability to synthesize a wide range of terpenoids, many unique to this taxon, and we present recent advancements in genomics and genetic engineering tools developed for Agaricomycetes. We anticipate that continued progress in tailored genetic engineering tools and improved cultivation technologies will facilitate the establishment of these fungi as robust cell factories for producing valuable terpenoids, with significant contributions to the food, biotech, and pharmaceutical sectors. One-Sentence Summary: This minireview highlights the potential of mushroom-forming fungi to be engineered into cell factories for producing terpenoids-valuable compounds with diverse applications in food, medicine, and biotechnology.

Indexed as

AgaricalesBasidiomycotaMetabolic EngineeringTerpenesBiotechnologyGenetic EngineeringIndustrial MicrobiologyTerpenesAgaricomycetesBiotechnologyCell factoriesMushroomsTerpenoids

Identifiers

PMID40650568
PMCPMC12345202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.